MarginsXMarginsX
Home › Markets › Health Care › MLTX

MoonLake Immunotherapeutics (MLTX)

MLTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.73
-6.16% on the day
Market cap
$998.3M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerMLTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001821586
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
18.7 months
$379.7M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$81.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$379.7M cash; operating cash flow -$61.0M a quarter.Report 2026-09-30
Shares outstanding85,106,685 (2026-11-01).Cover page 2026-11-01
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, Santa Clara, California, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $99K, sold $81.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$79.5M-$63.4M$379.7M$100.0MNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$61.8M-$55.6M$477.9M$99.5MNeeds four quarters10-Q 2026-08-10
Q1 2026
2026-03-31
Not filed-$69.7M-$66.3M$298.5M$99.0MNeeds four quarters10-Q 2026-05-11
Q4 2025
2025-12-31
Not filed-$62.4M-$58.8M$334.5M$74.1MNeeds four quarters10-K 2026-02-25
Q3 2025
2025-09-30
Not filed-$69.7M-$44.5M$350.7M$73.7MNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$55.2M-$54.5M$306.7M$73.4MNeeds four quarters10-Q 2026-08-10
Q1 2025
2025-03-31
Not filed-$39.9M-$38.1M$271.6M$73.0MNeeds four quarters10-Q 2026-05-11
Q4 2024
2024-12-31
Not filed-$45.6M-$48.5M$180.4M$0Needs four quarters10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-3ASR2026-08-10
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 331 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.4%
1 month+20.1%
3 months-24.2%
Year to date-5.2%
1 year-0.5%
From 52-week high-43.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CYRXCryoPort Inc.$19.80-0.45%$1.0B
SVRASavara Inc.$4.46-3.77%$985.1M
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
VSTMVerastem Inc.$7.70-5.87%$970.3M
MTRIMentari Therapeutics Inc.$19.87+6.83%$1.0B
ANROAlto Neuroscience Inc.$27.12-8.19%$1.1B
HROWHarrow Inc.$29.09-3.42%$1.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier